| Symbol | INO |
|---|---|
| Name | INOVIO PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical/Dental Instruments |
| Address | 660 W. GERMANTOWN PIKE,SUITE 110, PLYMOUTH MEETING, Pennsylvania, 19462, United States |
| Telephone | +1 -267 440-4200 |
| Fax | — |
| — | |
| Website | https://www.inovio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001055726 |
| Description | Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies. Additional info from NASDAQ: |
2026-05-13 20:07
(30% Negative) INOVIO PHARMACEUTICALS, INC. (INO) Reports Q2 2026 Financial Results
Read more
2026-05-13 20:06
INOVIO - INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
Read more
2026-05-13 20:05
INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
Read more
2026-05-13 10:07
New Form SCHEDULE 13G/A - INOVIO PHARMACEUTICALS, INC. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0000919574-26-002915 <b>Size:</b> 13 KB
Read more
2026-05-06 12:24
New Form SCHEDULE 13G/A - INOVIO PHARMACEUTICALS, INC. <b>Filed:</b> 2026-05-06 <b>AccNo:</b> 0000315066-26-001216 <b>Size:</b> 11 KB
Read more
2026-05-01 20:06
INOVIO - INOVIO to Report First Quarter Financial Results on May 13, 2026
Read more
2026-04-07 17:12
New Form DEF 14A - INOVIO PHARMACEUTICALS, INC. <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0001055726-26-000011 <b>Size:</b> 8 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05781542 | Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Enco… | Phase1 | HIV Infections | Completed | 2023-04-10 | 2025-04-14 | ClinicalTrials.gov |
| NCT05430958 | Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volu… | Phase1 | Coronavirus Infection | Withdrawn | 2022-10-01 | 2024-03-01 | ClinicalTrials.gov |
| NCT05293249 | dMAbs for Prevention of COVID-19 | Phase1 | Healthy Volunteers | Completed | 2022-05-19 | 2025-11-21 | ClinicalTrials.gov |
| NCT04906629 | INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees | Phase1 | Ebola Virus Disease | Completed | 2021-09-01 | 2022-05-11 | ClinicalTrials.gov |
| NCT04367675 | INO 5401 Vaccination in BRCA1/2 Mutation Carriers | Phase1 | BRCA1/2 Mutation | Active_Not_Recruiting | 2021-04-20 | 2027-03-01 | ClinicalTrials.gov |
| NCT04642638 | Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High… | Phase2 | Coronavirus Infection | Terminated | 2020-11-30 | 2022-09-13 | ClinicalTrials.gov |
| NCT04398433 | INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-As… | Phase1 | Respiratory Papillomatosis | Completed | 2020-10-07 | 2022-12-15 | ClinicalTrials.gov |
| NCT03721978 | REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of… | Phase3 | Cervical Dysplasia | Completed | 2019-02-28 | 2022-09-15 | ClinicalTrials.gov |
| NCT03831503 | A Study of INO-A002 in Healthy Dengue Virus-naive Adults | Phase1 | Healthy Volunteers | Completed | 2019-02-07 | 2022-10-03 | ClinicalTrials.gov |
| NCT03603808 | VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade … | Phase2 | Anal Intraepithelial Neoplasia | Completed | 2018-09-21 | 2025-06-17 | ClinicalTrials.gov |
| NCT03674125 | Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Hea… | Phase1 | HCV Infection | Completed | 2018-09-04 | 2020-05-04 | ClinicalTrials.gov |
| NCT03721718 | Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healt… | Phase1 | Healthy | Completed | 2018-08-28 | 2020-04-22 | ClinicalTrials.gov |
| NCT03606213 | Therapeutic Vaccination in Treated HIV Disease | Phase1 | HIV-1-infection | Completed | 2018-08-01 | 2021-05-17 | ClinicalTrials.gov |
| NCT03491683 | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cem… | Phase1 | Glioblastoma | Active_Not_Recruiting | 2018-05-31 | 2026-12-31 | ClinicalTrials.gov |
| NCT03502785 | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unrese… | Phase1 | Urothelial Carcinoma | Completed | 2018-05-24 | 2025-05-09 | ClinicalTrials.gov |
| NCT03499795 | VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for th… | Phase2 | Anal Neoplasm | Completed | 2018-05-15 | 2021-05-26 | ClinicalTrials.gov |
| NCT03180684 | Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquim… | Phase2 | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) | Completed | 2017-08-31 | 2020-12-18 | ClinicalTrials.gov |
| NCT03185013 | REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervi… | Phase3 | Cervical Dysplasia | Completed | 2017-06-28 | 2021-04-06 | ClinicalTrials.gov |
| NCT02887482 | GLS-5700 in Dengue Virus Seropositive Adults | Phase1 | Healthy | Completed | 2016-08-01 | 2018-06-01 | ClinicalTrials.gov |
| NCT02809443 | GLS-5700 in Dengue Virus-Naïve Adults | Phase1 | Healthy | Completed | 2016-07-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02772003 | DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infecti… | Phase1 | Chronic Hepatitis | Active_Not_Recruiting | 2016-06-06 | 2027-03-09 | ClinicalTrials.gov |
| NCT02501278 | A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in… | Phase2 | Uterine Cervical Neoplasms | Withdrawn | 2016-05-01 | 2021-05-01 | ClinicalTrials.gov |
| NCT02670187 | Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers | Phase1 | Healthy | Completed | 2016-02-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT02514213 | Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 … | Phase1 | Prostate Cancer | Completed | 2015-07-01 | 2017-12-12 | ClinicalTrials.gov |
| NCT02464670 | Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Fo… | Phase1 | Ebola Vaccine | Completed | 2015-05-01 | 2018-05-24 | ClinicalTrials.gov |
| NCT02431312 | Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B … | Phase1 | Hepatitis B | Completed | 2015-01-12 | 2018-05-22 | ClinicalTrials.gov |
| NCT02960594 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electrop… | Phase1 | Breast Cancer | Completed | 2014-12-01 | 2018-11-09 | ClinicalTrials.gov |
| NCT02163057 | Study of HPV Specific Immunotherapy in Participants With HPV Associated Head an… | Phase1 | Head and Neck Squamous Cell Cancer | Completed | 2014-08-13 | 2017-01-23 | ClinicalTrials.gov |
| NCT02172911 | A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervi… | Phase1 | Cervical Cancer | Completed | 2014-06-06 | 2017-09-07 | ClinicalTrials.gov |
| NCT02241369 | Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesi… | Phase1 | Aerodigestive Precancerous Lesions and Malignancies | Completed | 2014-05-01 | 2018-09-01 | ClinicalTrials.gov |
| NCT02027116 | Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-61… | Phase1 | Hepatitis C, Chronic | Completed | 2014-01-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT01587131 | DNA-based Influenza Vaccine in the Elderly | Phase1 | Influenza, Human | Completed | 2012-06-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01405885 | A Study of DNA Vaccine With Electroporation for the Prevention of Disease Cause… | Phase1 | Healthy | Completed | 2011-05-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01403155 | A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in… | Phase1 | Healthy | Completed | 2011-05-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01304524 | A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical … | Phase2 | Cervical Intraepithelial Neoplasia | Completed | 2011-04-01 | 2015-04-01 | ClinicalTrials.gov |
| NCT01335711 | CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV… | Phase2 | Chronic Hepatitis C | Unknown | 2011-04-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01334060 | WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by … | Phase2 | Leukaemia (Acute) | Completed | 2011-02-01 | 2013-02-26 | ClinicalTrials.gov |
| NCT01082692 | Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult P… | Phase1 | HIV-1 Infection | Completed | 2011-01-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01184976 | Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device… | Phase1 | Healthy | Completed | 2010-08-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01188850 | Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult … | Phase1 | Human Papillomavirus (HPV) | Completed | 2010-07-01 | 2011-10-20 | ClinicalTrials.gov |
| NCT01142362 | Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in… | Phase1 | Healthy | Completed | 2010-06-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00685412 | Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation … | Phase1 | Papillomavirus Infections | Completed | 2008-05-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT00563173 | Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients | Phase1 | Chronic Hepatitis C Virus Infection | Unknown | 2007-10-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00721461 | A Study to Test the Tolerability of an Investigational Electroporation Device i… | Phase1 | Healthy | Completed | 2005-07-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00198328 | Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck… | Phase3 | Head Neck Cancer | Terminated | 2004-11-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00198315 | Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck … | Phase3 | Head and Neck Cancer | Terminated | 2004-06-01 | 2007-06-01 | ClinicalTrials.gov |
| NCT00198276 | Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutane… | Phase4 | Cancer | Completed | 2004-02-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00198263 | Study Using the Medpulser Electroporation System With Bleomycin to Treat Head a… | Phase4 | Head and Neck Cancer | Completed | 2004-01-01 | 2008-09-01 | ClinicalTrials.gov |
Total clinical trials: 48
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Temozolomide | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Radiation Therapy | Drug | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Cemiplimab | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-9012 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-5401 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Temozolomide | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Radiation Therapy | Drug | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Cemiplimab | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-9012 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-5401 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Temozolomide | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Radiation Therapy | Drug | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Cemiplimab | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-9012 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-5401 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Temozolomide | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Radiation Therapy | Drug | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Cemiplimab | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-9012 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-5401 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Temozolomide | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Radiation Therapy | Drug | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Cemiplimab | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-9012 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-5401 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Temozolomide | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Radiation Therapy | Drug | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Cemiplimab | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-9012 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-5401 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Temozolomide | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Radiation Therapy | Drug | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Cemiplimab | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-9012 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-5401 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Temozolomide | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Radiation Therapy | Drug | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Cemiplimab | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-9012 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-5401 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Temozolomide | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Radiation Therapy | Drug | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Cemiplimab | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-9012 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-5401 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Temozolomide | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Radiation Therapy | Drug | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Cemiplimab | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-9012 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-5401 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Temozolomide | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Radiation Therapy | Drug | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Cemiplimab | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-9012 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-5401 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Cisplatin chemotherapy | Drug | Phase PHASE2 | Uterine Cervical Neoplasms | WITHDRAWN | NCT02501278 |
| Radiotherapy (Extrernal beam radiotherapy + brachytherapy) | Drug | Phase PHASE2 | Uterine Cervical Neoplasms | WITHDRAWN | NCT02501278 |
| INO-3112 vaccine | Other | Phase PHASE2 | Uterine Cervical Neoplasms | WITHDRAWN | NCT02501278 |
| CELLECTRA™-5P | Other | Phase PHASE1 | Cervical Cancer | COMPLETED | NCT02172911 |
| INO-3112 | Other | Phase PHASE1 | Cervical Cancer | COMPLETED | NCT02172911 |
| CELLECTRA™-5PSP | Other | Phase PHASE3 | Cervical Dysplasia | COMPLETED | NCT03721978 |
| Matched Placebo | Other | Phase PHASE3 | Cervical Dysplasia | COMPLETED | NCT03721978 |
| VGX-3100 | Other | Phase PHASE3 | Cervical Dysplasia | COMPLETED | NCT03721978 |
| SOC | Other | Phase PHASE2 | Chronic Hepatitis C | UNKNOWN | NCT01335711 |
| ChronVac-C + SOC | Other | Phase PHASE2 | Chronic Hepatitis C | UNKNOWN | NCT01335711 |
| PENNVAX-B | Other | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT01082692 |
| Seasonal Influenza vaccine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01405885 |
| INO-3510 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01405885 |
| INO-3605 AND INO-3609 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01405885 |
| INO-3401 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01405885 |
| INO-3609 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01405885 |
| INO-3605 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01405885 |
| VGX-3400 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01184976 |
| FVH1 - a DNA-based influenza vaccine | Other | Phase PHASE1 | Influenza, Human | COMPLETED | NCT01587131 |
| VGX-6150 | Other | Phase PHASE1 | Hepatitis C, Chronic | COMPLETED | NCT02027116 |
| INO-3401 + EP | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01403155 |
| VGX-3400X | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01142362 |
| Electroporation using CELLECTRA®-5P | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02514213 |
| 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P | Device | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02514213 |
| 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P | Device | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02514213 |
| 8.5mg INO-5150 and electroporation device CELLECTRA®-5P | Device | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02514213 |
| 2mg INO-5150 and electroporation device CELLECTRA®-5P | Device | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02514213 |
| VGX-3100 | Other | Phase PHASE1 | Human Papillomavirus (HPV) | COMPLETED | NCT01188850 |
| p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine | Other | Phase PHASE2 | Leukaemia (Acute) | COMPLETED | NCT01334060 |
| CELLECTRA™-5P | Other | Phase PHASE2 | Cervical Intraepithelial Neoplasia | COMPLETED | NCT01304524 |
| Placebo | Other | Phase PHASE2 | Cervical Intraepithelial Neoplasia | COMPLETED | NCT01304524 |
| VGX 3100 | Other | Phase PHASE2 | Cervical Intraepithelial Neoplasia | COMPLETED | NCT01304524 |
| INO-3106, INO-9012 | Other | Phase PHASE1 | Aerodigestive Precancerous Lesions and Malignancies | COMPLETED | NCT02241369 |
| INO-1401 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02960594 |
| INO-9012 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02960594 |
| INO-1400 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02960594 |
| GLS-5300 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02670187 |
| INO-4201 + INO-9012 | Other | Phase PHASE1 | Ebola Vaccine | COMPLETED | NCT02464670 |
| INO-4212 + INO-9012 | Other | Phase PHASE1 | Ebola Vaccine | COMPLETED | NCT02464670 |
| INO-4212 | Other | Phase PHASE1 | Ebola Vaccine | COMPLETED | NCT02464670 |
| INO-4202 | Other | Phase PHASE1 | Ebola Vaccine | COMPLETED | NCT02464670 |
| INO-4201 | Other | Phase PHASE1 | Ebola Vaccine | COMPLETED | NCT02464670 |
| Nucleos(t)ide Analogue Treatment | Drug | Phase PHASE1 | Hepatitis B | COMPLETED | NCT02431312 |
| INO-9112 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT02431312 |
| INO-1800 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT02431312 |
| Cellectra 2000 Electroporation | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03721718 |
| GLS-5300 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03721718 |
| GLS-6150 | Other | Phase PHASE1 | HCV Infection | COMPLETED | NCT03674125 |
| CELLECTRA™-5P | Other | Phase PHASE1 | Head and Neck Squamous Cell Cancer | COMPLETED | NCT02163057 |
| INO-3112 | Other | Phase PHASE1 | Head and Neck Squamous Cell Cancer | COMPLETED | NCT02163057 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02887482 |
| GLS-5700 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02887482 |
| Placebo | Other | Phase PHASE1 | Ebola Virus Disease | COMPLETED | NCT04906629 |
| INO-4201 | Other | Phase PHASE1 | Ebola Virus Disease | COMPLETED | NCT04906629 |
| CELLECTRA® 2000 | Other | Phase PHASE1 | Coronavirus Infection | WITHDRAWN | NCT05430958 |
| INO-9112 | Other | Phase PHASE1 | Coronavirus Infection | WITHDRAWN | NCT05430958 |
| INO-4800 | Other | Phase PHASE1 | Coronavirus Infection | WITHDRAWN | NCT05430958 |
| CELLECTRA® 2000 | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT03606213 |
| INO-9012 | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT03606213 |
| INO-6145 | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT03606213 |
| PENNVAX-GP | Other | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT03606213 |
| CELLECTRA™ 5PSP | Other | Phase PHASE2 | Anal Neoplasm | COMPLETED | NCT03499795 |
| VGX-3100 | Other | Phase PHASE2 | Anal Neoplasm | COMPLETED | NCT03499795 |
| Electroporation (EP) | Other | Phase PHASE3 | Cervical Dysplasia | COMPLETED | NCT03185013 |
| Placebo | Other | Phase PHASE3 | Cervical Dysplasia | COMPLETED | NCT03185013 |
| VGX-3100 | Other | Phase PHASE3 | Cervical Dysplasia | COMPLETED | NCT03185013 |
| CELLECTRA™ 2000 | Other | Phase PHASE2 | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) | COMPLETED | NCT03180684 |
| Imiquimod 5% Cream | Other | Phase PHASE2 | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) | COMPLETED | NCT03180684 |
| VGX-3100 | Other | Phase PHASE2 | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) | COMPLETED | NCT03180684 |
| Dengue Fever Antibodies (IgG) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03831503 |
| CELLECTRA® 2000 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03831503 |
| INO-A002 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03831503 |
| Placebo | Other | Phase PHASE2 | Coronavirus Infection | TERMINATED | NCT04642638 |
| CELLECTRA® 2000 | Other | Phase PHASE2 | Coronavirus Infection | TERMINATED | NCT04642638 |
| INO-4800 | Other | Phase PHASE2 | Coronavirus Infection | TERMINATED | NCT04642638 |
| GLS-5700 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02809443 |
| CELLECTRA™ 2000 | Other | Phase PHASE1 | Urothelial Carcinoma | COMPLETED | NCT03502785 |
| Atezolizumab | Other | Phase PHASE1 | Urothelial Carcinoma | COMPLETED | NCT03502785 |
| INO-9012 | Other | Phase PHASE1 | Urothelial Carcinoma | COMPLETED | NCT03502785 |
| INO-5401 | Other | Phase PHASE1 | Urothelial Carcinoma | COMPLETED | NCT03502785 |
| Alum | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT05781542 |
| 3M-052-AF | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT05781542 |
| Trimer 4571 | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT05781542 |
| IL-12 DNA | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT05781542 |
| sD-NP-GT8 DNA | Other | Phase PHASE1 | HIV Infections | COMPLETED | NCT05781542 |
| CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device | Device | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05293249 |
| Hylenex | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05293249 |
| CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device | Device | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05293249 |
| dMAb AZD8076 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05293249 |
| dMAb AZD5396 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05293249 |
| Cellectra 2000 | Other | Phase PHASE1 | BRCA1/2 Mutation | ACTIVE_NOT_RECRUITING | NCT04367675 |
| INO-9012 | Other | Phase PHASE1 | BRCA1/2 Mutation | ACTIVE_NOT_RECRUITING | NCT04367675 |
| INO-5401 | Other | Phase PHASE1 | BRCA1/2 Mutation | ACTIVE_NOT_RECRUITING | NCT04367675 |
| Temozolomide | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Radiation Therapy | Drug | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Cemiplimab | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-9012 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-5401 | Other | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Rocakinogene Sifuplasmid | Other | Phase PHASE1 | Chronic Hepatitis | ACTIVE_NOT_RECRUITING | NCT02772003 |
| Quality-of-Life Assessment | Other | Phase PHASE1 | Chronic Hepatitis | ACTIVE_NOT_RECRUITING | NCT02772003 |
| Laboratory Biomarker Analysis | Other | Phase PHASE1 | Chronic Hepatitis | ACTIVE_NOT_RECRUITING | NCT02772003 |
| HCV DNA Vaccine INO-8000 | Other | Phase PHASE1 | Chronic Hepatitis | ACTIVE_NOT_RECRUITING | NCT02772003 |
| Electroporation-Mediated Plasmid DNA Vaccine Therapy | Drug | Phase PHASE1 | Chronic Hepatitis | ACTIVE_NOT_RECRUITING | NCT02772003 |
| CELLECTRA® 2000 | Other | Phase PHASE1 | Respiratory Papillomatosis | COMPLETED | NCT04398433 |
| INO-3107 | Other | Phase PHASE1 | Respiratory Papillomatosis | COMPLETED | NCT04398433 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | Other | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Alum | DRUG | Phase PHASE1 | HIV Infections | COMPLETED | NCT05781542 |
| 3M-052-AF | BIOLOGICAL | Phase PHASE1 | HIV Infections | COMPLETED | NCT05781542 |
| Trimer 4571 | BIOLOGICAL | Phase PHASE1 | HIV Infections | COMPLETED | NCT05781542 |
| IL-12 DNA | BIOLOGICAL | Phase PHASE1 | HIV Infections | COMPLETED | NCT05781542 |
| sD-NP-GT8 DNA | BIOLOGICAL | Phase PHASE1 | HIV Infections | COMPLETED | NCT05781542 |
| Hylenex | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05293249 |
| INO-4700 | DRUG | Phase PHASE2 | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | COMPLETED | NCT04588428 |
| Saline-sodium citrate (SSC) buffer | OTHER | Phase PHASE1 | Coronavirus Infection | COMPLETED | NCT04447781 |
| INO-3107 | DRUG | Phase PHASE1 | Respiratory Papillomatosis | COMPLETED | NCT04398433 |
| Cellectra 2000 | DEVICE | Phase PHASE1 | BRCA1/2 Mutation | ACTIVE_NOT_RECRUITING | NCT04367675 |
| INO-4800 | DRUG | Phase PHASE1 | Coronavirus Infection | WITHDRAWN | NCT05430958 |
| Dengue Fever Antibodies (IgG) | DEVICE | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03831503 |
| INO-A002 | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT03831503 |
| INO-4500 | DRUG | Phase PHASE1 | Lassa Fever | COMPLETED | NCT04093076 |
| CELLECTRA™-5PSP | DEVICE | Phase PHASE3 | Cervical Dysplasia | COMPLETED | NCT03721978 |
| Matched Placebo | BIOLOGICAL | Phase PHASE3 | Cervical Dysplasia | COMPLETED | NCT03721978 |
| Cellectra 2000 Electroporation | DEVICE | Phase PHASE1 | Healthy | COMPLETED | NCT03721718 |
| GLS-6150 | BIOLOGICAL | Phase PHASE1 | HCV Infection | COMPLETED | NCT03674125 |
| CELLECTRA® 2000 | DEVICE | Phase PHASE1 | Coronavirus Infection | WITHDRAWN | NCT05430958 |
| INO-6145 | BIOLOGICAL | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT03606213 |
| PENNVAX-GP | BIOLOGICAL | Phase PHASE1 | HIV-1-infection | COMPLETED | NCT03606213 |
| HPV DNA Plasmids Therapeutic Vaccine VGX-3100 | BIOLOGICAL | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Electroporation | DEVICE | Phase PHASE2 | Anal Intraepithelial Neoplasia | COMPLETED | NCT03603808 |
| Atezolizumab | DRUG | Phase PHASE1 | Urothelial Carcinoma | COMPLETED | NCT03502785 |
| CELLECTRA™ 5PSP | DEVICE | Phase PHASE2 | Anal Neoplasm | COMPLETED | NCT03499795 |
| Temozolomide | DRUG | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Radiation Therapy | RADIATION | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| Cemiplimab | BIOLOGICAL | Phase PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT03491683 |
| INO-5401 | DRUG | Phase PHASE1 | BRCA1/2 Mutation | ACTIVE_NOT_RECRUITING | NCT04367675 |
| Electroporation (EP) | DEVICE | Phase PHASE3 | Cervical Dysplasia | COMPLETED | NCT03185013 |
| CELLECTRA™ 2000 | DEVICE | Phase PHASE2 | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | COMPLETED | NCT04588428 |
| Imiquimod 5% Cream | DRUG | Phase PHASE2 | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) | COMPLETED | NCT03180684 |
| INO-1401 | BIOLOGICAL | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02960594 |
| INO-9012 | DRUG | Phase PHASE1 | BRCA1/2 Mutation | ACTIVE_NOT_RECRUITING | NCT04367675 |
| INO-1400 | BIOLOGICAL | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02960594 |
| GLS-5700 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT02887482 |
| Rocakinogene Sifuplasmid | BIOLOGICAL | Phase PHASE1 | Chronic Hepatitis | ACTIVE_NOT_RECRUITING | NCT02772003 |
| Quality-of-Life Assessment | OTHER | Phase PHASE1 | Chronic Hepatitis | ACTIVE_NOT_RECRUITING | NCT02772003 |
| Laboratory Biomarker Analysis | OTHER | Phase PHASE1 | Chronic Hepatitis | ACTIVE_NOT_RECRUITING | NCT02772003 |
| HCV DNA Vaccine INO-8000 | BIOLOGICAL | Phase PHASE1 | Chronic Hepatitis | ACTIVE_NOT_RECRUITING | NCT02772003 |
| Electroporation-Mediated Plasmid DNA Vaccine Therapy | BIOLOGICAL | Phase PHASE1 | Chronic Hepatitis | ACTIVE_NOT_RECRUITING | NCT02772003 |
| GLS-5300 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT03721718 |
| Electroporation using CELLECTRA®-5P | DEVICE | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02514213 |
| 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P | BIOLOGICAL | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02514213 |
| 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P | BIOLOGICAL | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02514213 |
| 8.5mg INO-5150 and electroporation device CELLECTRA®-5P | BIOLOGICAL | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02514213 |
| 2mg INO-5150 and electroporation device CELLECTRA®-5P | BIOLOGICAL | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02514213 |
| Cisplatin chemotherapy | DRUG | Phase PHASE2 | Uterine Cervical Neoplasms | WITHDRAWN | NCT02501278 |
| Radiotherapy (Extrernal beam radiotherapy + brachytherapy) | RADIATION | Phase PHASE2 | Uterine Cervical Neoplasms | WITHDRAWN | NCT02501278 |
| INO-3112 vaccine | BIOLOGICAL | Phase PHASE2 | Uterine Cervical Neoplasms | WITHDRAWN | NCT02501278 |
| INO-4201 + INO-9012 | BIOLOGICAL | Phase PHASE1 | Ebola Vaccine | COMPLETED | NCT02464670 |
| INO-4212 + INO-9012 | BIOLOGICAL | Phase PHASE1 | Ebola Vaccine | COMPLETED | NCT02464670 |
| INO-4212 | BIOLOGICAL | Phase PHASE1 | Ebola Vaccine | COMPLETED | NCT02464670 |
| INO-4202 | BIOLOGICAL | Phase PHASE1 | Ebola Vaccine | COMPLETED | NCT02464670 |
| INO-4201 | BIOLOGICAL | Phase PHASE1 | Ebola Virus Disease | COMPLETED | NCT04906629 |
| Nucleos(t)ide Analogue Treatment | DRUG | Phase PHASE1 | Hepatitis B | COMPLETED | NCT02431312 |
| INO-9112 | DRUG | Phase PHASE1 | Coronavirus Infection | WITHDRAWN | NCT05430958 |
| INO-1800 | BIOLOGICAL | Phase PHASE1 | Hepatitis B | COMPLETED | NCT02431312 |
| INO-3106, INO-9012 | BIOLOGICAL | Phase PHASE1 | Aerodigestive Precancerous Lesions and Malignancies | COMPLETED | NCT02241369 |
| INO-3112 | BIOLOGICAL | Phase PHASE1 | Cervical Cancer | COMPLETED | NCT02172911 |
| VGX-6150 | BIOLOGICAL | Phase PHASE1 | Hepatitis C, Chronic | COMPLETED | NCT02027116 |
| FVH1 - a DNA-based influenza vaccine | BIOLOGICAL | Phase PHASE1 | Influenza, Human | COMPLETED | NCT01587131 |
| Seasonal Influenza vaccine | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT01405885 |
| INO-3510 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT01405885 |
| INO-3605 AND INO-3609 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT01405885 |
| INO-3401 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT01405885 |
| INO-3609 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT01405885 |
| INO-3605 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT01405885 |
| INO-3401 + EP | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT01403155 |
| SOC | DRUG | Phase PHASE2 | Chronic Hepatitis C | UNKNOWN | NCT01335711 |
| ChronVac-C + SOC | DRUG | Phase PHASE2 | Chronic Hepatitis C | UNKNOWN | NCT01335711 |
| p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine | BIOLOGICAL | Phase PHASE2 | Leukaemia (Acute) | COMPLETED | NCT01334060 |
| CELLECTRA™-5P | DEVICE | Phase PHASE1 | Cervical Cancer | COMPLETED | NCT02172911 |
| Placebo | BIOLOGICAL | Phase PHASE1 | Ebola Virus Disease | COMPLETED | NCT04906629 |
| VGX 3100 | BIOLOGICAL | Phase PHASE2 | Cervical Intraepithelial Neoplasia | COMPLETED | NCT01304524 |
| VGX-3400 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT01184976 |
| VGX-3400X | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT01142362 |
| PENNVAX-B | BIOLOGICAL | Phase PHASE1 | HIV-1 Infection | COMPLETED | NCT01082692 |
| V930 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT00721461 |
| VGX-3100 | BIOLOGICAL | Phase PHASE3 | Cervical Dysplasia | COMPLETED | NCT03721978 |
| CHRONVAC-C® | DRUG | Phase PHASE1 | Chronic Hepatitis C Virus Infection | UNKNOWN | NCT00563173 |
| Surgical Excision | PROCEDURE | Phase PHASE3 | Head Neck Cancer | TERMINATED | NCT00198328 |
| Tumor surgical excision | PROCEDURE | Phase PHASE3 | Head and Neck Cancer | TERMINATED | NCT00198315 |
Total products: 291